Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

Table 3 Predictive factors for good downstaging in univariate logistic regression analysis for all patients

Variable		Bad downstaging (n = 226) n P50 (P25-P75)	Good downstaging (n = 177) n P50 (P25-P75)	Good downstaging rate	P-value
Gender	Male	164	117	41.64%	0.106
	Female	59	60	50.42%
Age (yr)	≤ 60	144	120	45.45%	0.462
	> 60	80	57	41.61%
BMI (kg/cm2)	< 25	159	125	44.01%	0.475
	≥ 25	56	37	39.78%
Hemoglobin (g/L)	≤ 125	69	56	44.80%	0.426
	> 125	127	86	40.38%
NLR	> 3	27	21	43.75%	0.792
	≤ 3	169	121	41.72%
Platelet (×109/L)		241 (207-294)	236 (193-272.25)		0.125
ApoA1 (g/L)		1.27 (1.13-1.44)	1.31 (1.15-1.48)		0.228
ApoB (g/L)		0.98 (0.79-1.13)	0.97 (0.79-1.18)		0.88
The interval		39 (23-54)	48 (25.75-55)		0.062
CEA (ng/mL)	> 5	125	66	34.55%	0.002
	≤ 5	71	76	51.70%
Differentiation	Moderate-poor	194	124	38.99%	0
	Well	20	44	68.75%
DTAV (cm)	< 5	85	96	53.04%	0.001
	≥ 5	141	81	36.49%
TL (cm)	> 3	167	111	39.93%	0.002
	≤ 3	44	59	57.28%
TCE	< 50%	23	21	47.73%	0.508
	≥ 50%	179	132	42.44%
cT	2	4	17	80.95%	0
	3	160	130	44.83%
	4	46	16	25.81%
cN	+	166	126	43.15%	0.074
	-	43	50	53.76%
MRF	-	142	150	51.37%	0
	+	81	27	25.00%
NT regimen	Capecitabine/de Gramont-RT	64	51	44.35%	0.061
	mFOLFOX6-RT	61	65	51.59%
	mFOLFOX6	101	61	37.65%

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.